BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 16752412)

  • 1. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
    Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
    Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin and rank ligand expression in prostate cancer.
    Brown JM; Corey E; Lee ZD; True LD; Yun TJ; Tondravi M; Vessella RL
    Urology; 2001 Apr; 57(4):611-6. PubMed ID: 11306358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
    Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
    Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
    Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
    Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
    Hofbauer LC; Neubauer A; Heufelder AE
    Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells.
    Hasegawa T; Yoshimura Y; Kikuiri T; Yawaka Y; Takeyama S; Matsumoto A; Oguchi H; Shirakawa T
    J Periodontal Res; 2002 Dec; 37(6):405-11. PubMed ID: 12472833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
    Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
    Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
    J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
    Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
    World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars.
    Low E; Zoellner H; Kharbanda OP; Darendeliler MA
    Am J Orthod Dentofacial Orthop; 2005 Oct; 128(4):497-503. PubMed ID: 16214633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2004 Jan; 33(1):46-52. PubMed ID: 14675140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.